ProCE Banner Activity

Reducing Renal Risk in Patients with Type 2 Diabetes

Clinical Thought

An expert answers questions regarding renal risk reduction in patients with type 2 diabetes (T2D) as well as the efficacy of GLP-1 receptor agonists and SGLT2 inhibitors in the treatment of T2D and chronic kidney disease. The importance of patient education is also highlighted.

Released: November 26, 2024

Expiration: November 25, 2025

Share

Faculty

Jennifer B Green

Jennifer B Green, MD

Professor of Medicine
Division of Endocrinology
Department of Medicine
Duke Clinical Research Institute
Duke University Medical Center
Durham, North Carolina

Provided by

Provided by Clinical Care Options, LLC in partnership with Practicing Clinicians Exchange, LLC and the American Kidney Fund.

ProCE Banner

Supporters

Supported by an educational grant from Novo Nordisk.

Novo Nordisk

Partners

American Kidney Fund

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner

Faculty Disclosure

Primary Author

Jennifer B Green, MD

Professor of Medicine
Division of Endocrinology
Department of Medicine
Duke Clinical Research Institute
Duke University Medical Center
Durham, North Carolina

Jennifer B. Green, MD: consultant/advisor/speaker: Anji, AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, Mineralys, Novo Nordisk, Pfizer, Valo, Vertex; researcher: Bluedrop, Boehringer Ingelheim/Lilly, Merck, Roche.